Weight-Loss Medications: Is There a Link to Depression and Suicidal Thoughts?
Weight-loss medications have become increasingly popular in recent years, particularly drugs belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, including semaglutide, liraglutide, and tirzepatide. While these treatments have attracted considerable attention because of their effectiveness in reducing body weight, questions have also been raised about their potential psychiatric effects.
Reports of depression, suicidal thoughts, and self-harm among some people taking these medications prompted health authorities to investigate whether there could be a connection. However, current evidence does not establish that these treatments increase the risk of depression or suicidal thoughts.
Why did these medications raise concerns?
GLP-1 receptor agonists act on mechanisms involved in appetite regulation and satiety. Some are used to treat type 2 diabetes, while others are also approved for the management of overweight and obesity.
Reports of suicidal thoughts or behavior after these drugs entered the market led the U.S. Food and Drug Administration to conduct a safety evaluation. The objective was to determine whether these events could be related to the medications or whether other factors, including patients’ medical and psychological histories, might explain them.
In 2024, the FDA stated that its preliminary assessment had not found evidence of a causal relationship between GLP-1 receptor agonists and suicidal thoughts or actions.
The latest evidence is reassuring
In January 2026, the FDA announced the results of its comprehensive evaluation. Its analysis of 91 placebo-controlled clinical trials involving more than 107,000 participants found no increased risk of suicidal thoughts or behavior among people taking GLP-1 receptor agonists.
The analysis also found no increased risk of other relevant psychiatric events, including depression, anxiety, irritability, or psychosis. In addition, the FDA examined healthcare data involving more than two million patients to compare the risk of intentional self-harm among GLP-1 users with that of people taking other medications. No increased risk was identified.
Based on the totality of this evidence, the FDA requested that information concerning suicidal thoughts and behavior be removed from the labeling of certain medications, including liraglutide, semaglutide, and tirzepatide.
Why do some studies still raise concerns?
The issue has not completely disappeared from scientific discussion. Some analyses based on adverse-event reports collected after medications entered the market have detected signals involving depression, suicide, or self-harm among users of drugs such as semaglutide, liraglutide, and tirzepatide.
A 2025 study using data from the FDA Adverse Event Reporting System, or FAERS, examined these reports. Such pharmacovigilance analyses can be valuable for identifying potential safety signals, but they cannot by themselves establish that a medication caused the reported event.
People taking weight-loss medications may also have several factors that can affect mental health, including severe obesity, chronic disease, diabetes, chronic pain, body-image concerns, previous depression, or other psychiatric conditions. These factors make it particularly difficult to determine whether a mental-health problem is directly caused by a medication.
Should patients still monitor their mental health?
Although current evidence does not indicate an increased risk of suicidal behavior with GLP-1 receptor agonists, significant changes in mood should always be taken seriously.
Persistent sadness, loss of interest in normal activities, feelings of hopelessness, unusual anxiety, major behavioral changes, or the emergence of suicidal thoughts should be discussed promptly with a healthcare professional.
The FDA specifically advises patients to report new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior to their healthcare provider.
Do not stop treatment without medical advice
Concerns about possible psychiatric effects should not lead patients to stop treatment on their own. The decision to continue, modify, or discontinue a weight-loss medication should be made with a healthcare professional after considering the person’s overall health, expected benefits, and potential adverse effects.
It is also important to distinguish approved medications from unauthorized or compounded products that may not have undergone the same regulatory evaluation. In 2026, the FDA also raised concerns about certain non-approved compounded GLP-1 products marketed as alternatives to approved medicines.
Concerns about a possible connection between modern weight-loss medications and depression or suicidal thoughts have been the subject of substantial scientific and regulatory scrutiny. However, the strongest evidence currently available, including the FDA’s comprehensive 2026 evaluation, does not show that GLP-1 receptor agonists increase the risk of suicidal thoughts or behavior.
This does not mean that psychological symptoms should be ignored. Any new or worsening depression, suicidal thoughts, or major behavioral changes should be discussed promptly with a healthcare professional. If someone is experiencing immediate suicidal thoughts or is in imminent danger, emergency medical or crisis support should be sought without delay.
